Sign up to save your podcasts
Or
Share Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
Psychological Medicine
Using data from the EU-GEI case-control study and UK Biobank, researchers examined the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS), on risk for psychosis. Schizophrenia PRS and cannabis use independently increased risk of psychosis. Schizophrenia PRS was not associated with patterns of cannabis use. It was associated with lifetime and daily cannabis use without psychosis, but the effect was substantially reduced when cannabis use disorder (CUD) PRS was included in the model. Regular users of high-potency cannabis had the highest odds of being a case independently of schizophrenia PRS. Regular use of high-potency cannabis remains a strong predictor of psychotic disorder, independent of schizophrenia PRS. Schizophrenia PRS does not seem to be associated with heavy cannabis use. These are important findings, at a time of increasing use and potency of cannabis worldwide.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
View all episodes
By American Society of Addiction Medicine
4.9
77 ratings
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
Psychological Medicine
Using data from the EU-GEI case-control study and UK Biobank, researchers examined the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS), on risk for psychosis. Schizophrenia PRS and cannabis use independently increased risk of psychosis. Schizophrenia PRS was not associated with patterns of cannabis use. It was associated with lifetime and daily cannabis use without psychosis, but the effect was substantially reduced when cannabis use disorder (CUD) PRS was included in the model. Regular users of high-potency cannabis had the highest odds of being a case independently of schizophrenia PRS. Regular use of high-potency cannabis remains a strong predictor of psychotic disorder, independent of schizophrenia PRS. Schizophrenia PRS does not seem to be associated with heavy cannabis use. These are important findings, at a time of increasing use and potency of cannabis worldwide.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
More shows like This Week in Addiction Medicine from ASAM
View all
NEI Podcast
130 Listeners
JAMA Clinical Reviews
481 Listeners
AFP: American Family Physician Podcast
690 Listeners
Frankly Speaking About Family Medicine
254 Listeners
White Coat Investor Podcast
2,411 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
Core IM | Internal Medicine Podcast
1,095 Listeners
Addiction Medicine: Beyond the Abstract
28 Listeners
Psychopharmacology and Psychiatry Updates
282 Listeners
The Carlat Psychiatry Podcast
554 Listeners
The Curious Clinicians
362 Listeners
The Curbsiders Addiction Medicine Podcast
116 Listeners
Addiction Medicine Journal Club
31 Listeners
PsychRounds: The Psychiatry Podcast
102 Listeners